Brookline Capital Markets Starts Cyclacel Pharmaceuticals (CYCC) at Buy
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Cyclacel Pharmaceuticals (NASDAQ: CYCC) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Cyclacel Pharmaceuticals click here. For more ratings news on Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $4.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
- Needham Starts Horizon Quantum (HQ) at Buy
- HSBC Resumes Fortis Healthcare Ltd (FORH:IN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
